Adtran’s Coherent 100ZR and FSP 3000 OLS to play key role in OIF’s ECOC open interoperability showcase
20.9.2024 14:00:00 CEST | Business Wire | Press release
News summary: Adtran FSP 3000 open optical line system facilitates transport of coherent 100ZR and 400G OpenZR+ interfaces in OIF multi-vendor demo Demo spanning nearly 300km also features Adtran’s Coherent 100ZR QSFP28 pluggable transceiver for cost-effective, low-power 100G transport Collaboration with leading industry players highlights Adtran’s role in driving open, scalable optical networking solutions
Adtran today announced its key role in the Optical Internetworking Forum’s (OIF) demonstration of open, multi-vendor networking at the European Conference on Optical Communication (ECOC) 2024. At the center of the showcase are Adtran’s Coherent 100ZR QSFP28 pluggable module and its FSP 3000 open optical line system (OLS), which enables the transport of a wide range of data rates, including 100ZR and 400Gbit/s OpenZR+, as featured in this demo. Incorporating 100Gbit/s to 800Gbit/s coherent pluggable transceivers and various OLS technologies from multiple vendors, the demo showcases advancements in open optical networking and innovative vendor-neutral solutions, highlighting the importance of testing multi-vendor interoperability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240920990844/en/
Adtran’s central role in the OIF demo underlines its commitment to developing open solutions that seamlessly interoperate with other vendors. (Photo: Business Wire)
“Adtran continues to lead the way in promoting open, disaggregated networking. By integrating our FSP 3000 OLS with 100ZR and 400Gbit/s OpenZR+ transceivers from a wide range of vendors, including our coherent 100ZR QSFP28, we’re offering operators a cost-effective, low-power solution to enhance their data center interconnect (DCI) networks and cloud infrastructure. With its standards-compliant design, our coherent 100ZR facilitates multi-vendor interoperability for 100Gbit/s transmission up to 300km over any open line system, while the FSP 3000 OLS streamlines operations and ensures flexible, scalable transport with optimal performance,” said Christoph Glingener, CTO of Adtran. “This collaboration with the OIF and other major industry players demonstrates our commitment to providing open solutions that meet the evolving demands of the cloud and the optical edge.”
The joint solution on display showcases exceptional optical performance, with the Adtran FSP 3000 OLS ensuring streamlined setup and precise operation. Equipped with integrated monitoring and diagnostic functions, as well as a high level of automation, the FSP 3000 OLS simplifies management and optimizes transmission performance. The collaboration with industry leaders highlights Adtran’s commitment to open optical networking solutions and demonstrates how its technology is built to industry standards. This approach offers the flexibility and scalability needed to meet diverse customer requirements while advancing multi-vendor interoperability.
“For decades, we’ve been pioneers in the DCI space, enabling enterprises and cloud providers to build high-capacity, high-performance networks. Our solutions are built around an open environment, promoting innovation and seamless interoperability with other vendors. We’re proud to be at the heart of this large-scale demonstration, where our Coherent 100ZR and FSP 3000 OLS are driving the adoption of open, multi-vendor interoperability for data center applications,” commented Stephan Neidlinger, VP of global business development at Adtran. “By championing openness and collaboration across the industry, we’re advancing high-performance networking and reaffirming our leadership in delivering the technologies that will shape the future of optical networking.”
Visitors to ECOC can find out more about the demo at Adtran’s booth, D79, and the OIF’s booth, B83.
OIF Champions Interoperability at ECOC 2024: 34 Member Companies to Showcase Solutions for Data Centers, AI/ML Technologies and Disaggregated Systems
At ECOC 2024, OIF will host a dynamic interoperability demonstration, featuring live collaboration from 34 member companies shaping the future of connectivity. This showcase will highlight advanced solutions that are redefining performance, efficiency and capacity in response to the burgeoning needs of future-oriented data centers, AI/ML technologies and disaggregated systems. Attendees will discover cutting-edge interoperability solutions in 800ZR, 400ZR and Multi-span optics, along with innovations in Energy Efficient Interfaces (EEI) & Co-Packaging, 224G and 112G Common Electrical I/O (CEI) and Common Management Interface Specification (CMIS) that are crucial for shaping the next decade of industry standards. Visit us at booth #B83 for live, interactive demonstrations. For further details, please visit: https://www.oiforum.com/meetings-events/oif-ecoc-2024.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240920990844/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom